Brief: CytomX Therapeutics Announces First Patient Dosed With CX-2051 In Phase 1 Study In Patients With Advanced Solid Tumors
08/04/2024 14:35
April 8 (Reuters) - CytomX Therapeutics Inc CTMX.O :
* CYTOMX THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH
CX-2051,
A CONDITIONALLY ACTIVATED EPCAM-DIRECTED ADC, IN A PHASE 1 STUDY
IN PATIENTS WITH ADVANCED SOLID TUMORS
Source text for Eikon: ID:nGNX73zhYn
Further company coverage: CTMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway